Literature DB >> 8797971

MR cholangiopancreatography (MRCP) at 0.5 T: technique optimisation and preliminary results.

P Pavone1, A Laghi, C Catalano, L Broglia, A Messina, A Scipioni, M Di Girolamo, R Passariello.   

Abstract

The aim of our study was to evaluate the feasibility of MR cholangiopancreatography (MRCP) at 0.5 T. To our knowledge no previous studies of MRCP have been performed at mid-field strength. Thirty-one patients with dilated biliary systems were examined with three-dimensional MRCP. All patients were studied with a 0.5 T superconducting magnet. A three-dimensional turbo spin-echo (TSE) sequence was acquired (TR = 5000 ms, TE = 244 ms, echo train length = 45; acquisition time = 14 min 10 s). Coronal images were post-processed with the MIP algorithm. Recently, the parameters have been optimised (TR = 3000 ms, TE = 700 ms, echo train length = 128), reducing the acquisition time to 3 min. Endoscopic retrograde cholangiopancreatography (ERCP) was performed in 26 cases; 5 patients underwent percutaneous transhepatic cholangiography PTC. MRCP and ERCP images were evaluated by an experienced radiologist and an endoscopist. MRCP of diagnostic quality was acquired in all patients. Choledocholithiasis was correctly evaluated by MRCP in 12 of 12 patients, compared with 11 correct diagnoses by ERCP. The presence and the level of the stricture were accurately shown in 16 of 16 patients with MRCP and in 13 of 16 patients with ERCP. The peripheral biliary tree above the obstruction and pancreatic duct were better evaluated by MRCP in all cases. In 3 of 3 patients who had undergone bilio-enteric surgery, a correct evaluation of the site of the anastomosis was possible with MRCP. It is concluded that MRCP performed at mid-field strength allows good visualisation of the dilated biliary system. Excellent results have been obtained on comparison with ERCP. MRCP performed at mid-field strength could have the same clinical value as high field strength MRCP.

Entities:  

Mesh:

Year:  1996        PMID: 8797971     DOI: 10.1007/bf00181131

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  6 in total

1.  Biliary obstruction: evaluation with three-dimensional MR cholangiography.

Authors:  K Morimoto; M Shimoi; T Shirakawa; Y Aoki; S Choi; Y Miyata; K Hara
Journal:  Radiology       Date:  1992-05       Impact factor: 11.105

2.  Dilated biliary tract: evaluation with MR cholangiography with a T2-weighted contrast-enhanced fast sequence.

Authors:  B K Wallner; K A Schumacher; W Weidenmaier; J M Friedrich
Journal:  Radiology       Date:  1991-12       Impact factor: 11.105

3.  Breath-hold projection magnetic resonance-cholangio-pancreaticography (MRCP): a new method for the examination of the bile and pancreatic ducts.

Authors:  J Laubenberger; M Büchert; B Schneider; U Blum; J Hennig; M Langer
Journal:  Magn Reson Med       Date:  1995-01       Impact factor: 4.668

4.  Diagnosis of choledocholithiasis: value of MR cholangiography.

Authors:  L Guibaud; P M Bret; C Reinhold; M Atri; A N Barkun
Journal:  AJR Am J Roentgenol       Date:  1994-10       Impact factor: 3.959

5.  Breath-hold MR cholangiopancreatography with a long-echo-train fast spin-echo sequence and a surface coil in chronic pancreatitis.

Authors:  Y Takehara; K Ichijo; N Tooyama; N Kodaira; H Yamamoto; M Tatami; M Saito; H Watahiki; M Takahashi
Journal:  Radiology       Date:  1994-07       Impact factor: 11.105

6.  MR cholangiography: clinical evaluation in 40 cases.

Authors:  M A Hall-Craggs; C M Allen; C M Owens; B A Theis; J J Donald; M Paley; I D Wilkinson; W K Chong; A R Hatfield; W R Lees
Journal:  Radiology       Date:  1993-11       Impact factor: 11.105

  6 in total
  2 in total

Review 1.  Biliary tract imaging.

Authors:  E Corazziari
Journal:  Curr Gastroenterol Rep       Date:  1999-04

2.  Use of magnetic resonance cholangiography in the diagnosis of choledocholithiasis: prospective comparison with a reference imaging method.

Authors:  S H Zidi; F Prat; O Le Guen; Y Rondeau; L Rocher; J Fritsch; A D Choury; G Pelletier
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.